William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer (mCRPC).
In the phase II PRINT trial, patients received 3, 12-week cycles of sequential combination therapy. At a median follow-up of 1 year, 21.1% of patients did not require additional therapy.
Data from the trial is being evaluated to determine why some patients acquired prolonged disease-free intervals without the need for additional next-generation therapy, says Oh. Although the results shed light on benefits of each combination therapy in a relatively short period of time, investigators are also hoping to validate biomarkers of response to these combinations to help inform which patients are likely to benefit from this sequence of therapy.
Typically, older patients with mCRPC cannot tolerate multidrug combinations, says Oh. However, the treatments in the study were generally well tolerated.